相关实验视频

Updated: Sep 15, 2025

A BW Reporter System for Studying Receptor-Ligand Interactions

A BW Reporter System for Studying Receptor-Ligand Interactions

Published on: January 7, 2019

鉴定和评价本齐米达-天生的免疫受体NOD2的激动剂

Liora Wittle, Karl Ocius, Mahendra Chordia

bioRxiv : the preprint server for biology

|July 17, 2025

概括

研究人员发现了nocodazole,一种新型的小分子,可以激活NOD2 (核酸结合和寡合化域受体2). 这一发现为改进的NOD2向疗法提供了潜在的潜力,副作用更少.

科学领域:

免疫学免疫学免疫学
药理学药理学是指药理学的学科.
药物发现药物发现药物发现

背景情况:

与NOD2一样的模式识别受体 (PRRs) 在免疫反应和疾病中至关重要.
NOD2激活显示在营养不良,IBD和癌症免疫治疗中具有治疗潜力.
目前的NOD2激动剂 (MDP衍生物) 有诸如低生物利用性和副作用等局限性.

研究的目的:

确定激活NOD2.2的新型小分子.
发现具有改善药理性质的潜在治疗剂.
为了克服现有的NOD2激动剂的局限性.

主要方法:

选了1917年FDA批准的药物,使用表型测定用于NOD2激活.
鉴定出胺醇是NOD2激动剂的一类.
描述了诺可达的功效和下游效应.

主要成果:

诺科达是一种本齐米达衍生物,被确定为一种强大的NOD2激动剂.
诺可达以纳米分子强度激活NOD2.
诺可达诱导细胞因子释放类似于MDP,表明潜在的治疗性免疫效应.

结论:

诺可达是NOD2向治疗的有希望的新型小分子.
这一发现可能会通过利用NOD2激活来改善各种疾病的治疗方法.
与现有的基于MDP的NOD2激动剂相比,诺可达可能具有更好的药理特性.

更多相关视频

Screening Bioactive Nanoparticles in Phagocytic Immune Cells for Inhibitors of Toll-like Receptor Signaling

Screening Bioactive Nanoparticles in Phagocytic Immune Cells for Inhibitors of Toll-like Receptor Signaling

Published on: July 26, 2017

Activation and Measurement of NLRP3 Inflammasome Activity Using IL-1β in Human Monocyte-derived Dendritic Cells

Activation and Measurement of NLRP3 Inflammasome Activity Using IL-1β in Human Monocyte-derived Dendritic Cells

Published on: May 22, 2014

相关概念视频

Cells of the Innate Immune Response

Cells of the Innate Immune Response

The innate immune response is an immediate and non-specific response against pathogens, acting swiftly to prevent the spread of infections. The primary cells involved in this response are phagocytes and natural killer (NK) cells.
Phagocytes
Phagocytes police the peripheral tissues by removing cellular debris and responding to the invasion of foreign substances or pathogens. Many phagocytes attack and remove microorganisms even before lymphocytes detect them. The human body has two general...